ClinicalTrials.gg
CompletedNCT04716933Updated Sep 9, 2025Results posted

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

A Phase 3 interventional study of Pembrolizumab and Carboplatin in Nonsquamous Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2019, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with metastatic nonsquamous non-small cell lung cancer.

The primary study hypotheses state that: 1) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo+platinum doublet chemotherapy+pembrolizumab, and 2) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Overall Survival (OS) compared to matching placebo+platinum doublet chemotherapy + pembrolizumab.

Read the detailed description

The China extension study will include participants previously enrolled in mainland China for the global study for MK-7902-006 (NCT03829319) plus those enrolled in mainland China as part of the China extension enrollment period.

02

Conditions studied

  • Nonsquamous Non-small Cell Lung Cancer

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC], version 8 or current version) nonsquamous NSCLC.
  • Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation).
  • Have based on 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.
  • Provided an evaluable sample or newly obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) for central testing.
  • of at least 3 months.
  • (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.
  • Male participants must agree to use during the treatment period and for at least 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents. A male participant must also agree to the following: 1) abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR 2) agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of (WOCBP) who is not currently pregnant, unless confirmed to be azoospermic (vasectomized or secondary to medical cause). Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
  • Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) not a WOCBP OR 2) a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.
  • Adequate organ function.
  • Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as >150/90 mm Hg for >4 weeks despite standard medical management.

Exclusion criteria

Exclusion Criteria:

  • Known untreated central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable, clinically stable, and have not required for at least 14 days prior to the first dose of study intervention.
  • History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
  • Radiographic evidence of major blood vessel invasion/infiltration.
  • Known history of an additional , except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.
  • Active disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
  • Has had allogeneic tissue/solid organ transplant.
  • Known history of (HIV) infection. HIV testing is not required unless mandated by the local health authority.
  • Known history of or active . No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority.
  • History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.
  • Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.
  • Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.
  • Known history of active tuberculosis.
  • Active infection requiring systemic therapy.
  • Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.
  • Previously had a severe reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.
  • Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after last dose of chemotherapeutic agents.
  • Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of /adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.
  • Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, , anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.
  • Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of >30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  • Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.
  • Received a within 30 days prior to the first dose of study intervention.
  • Currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.
  • Has a prolongation of (calculated using Fridericia's formula) of >480 msec
  • (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
  • Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib

    Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Lenvatinib

  • Placebo comparator
    Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo

    Participants receive carboplatin AUC5 or cisplatin 75 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Placebo matching lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion Q3W

    Also known as: MK-3475

  • IV infusion Q3W

  • IV infusion Q3W

  • IV infusion Q3W

  • Oral capsule once daily

    Also known as: MK-7902, E7080

  • DrugPlacebo matching lenvatinib

    Oral capsule once daily

06

What researchers measure

Primary outcomes

  1. Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.

    Time frame: Up to approximately 43 months

  2. Part 2: Overall Survival (OS)

    OS is defined as the time from randomization to the time of death from any cause. OS is presented.

    Time frame: Up to approximately 43 months

Secondary outcomes

  1. Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.

    Time frame: Up to approximately 57 months

  2. Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.

    Time frame: Up to approximately 57 months

  3. Part 2: Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.

    Time frame: Up to approximately 42 months

  4. Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.

    Time frame: Up to approximately 42 months

07

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestonePemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Started101100
Completed00
Not completed101100
Withdrew: Sponsor decision3633
Withdrew: Death6567

Outcome measures

PrimaryPart 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)15.3 (12.2 to 19.6)9.2 (8.2 to 12.5)
Statistical analysis
  • Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib vs Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo · Hazard ratio (hr): 0.68 · 95% CI 0.48 to 0.97
PrimaryPart 2: Overall Survival (OS)

OS is defined as the time from randomization to the time of death from any cause. OS is presented.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Part 2: Overall Survival (OS)
MonthsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Overall Survival (OS)26.6 (22.2 to 35.0)22.0 (16.6 to 24.8)
Statistical analysis
  • Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib vs Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo · Hazard ratio (hr): 0.78 · 95% CI 0.54 to 1.12
SecondaryPart 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.

Time frame:
Up to approximately 57 months
Reported as:
Number · Percentage of participants
Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of participantsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)70.3 (60.4 to 79.0)59.0 (48.7 to 68.7)
Statistical analysis
  • Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib vs Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo · Percent difference: 11.3 · 95% CI -2.0 to 24.2
SecondaryPart 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.

Time frame:
Up to approximately 57 months
Reported as:
Median · Months
Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)17.0 (12.6 to 23.6)12.5 (6.7 to 27.5)
SecondaryPart 2: Number of Participants Who Experienced an Adverse Event (AE)

An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.

Time frame:
Up to approximately 42 months
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Number of Participants Who Experienced an Adverse Event (AE)101100
SecondaryPart 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.

Time frame:
Up to approximately 42 months
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo
Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event4221

Adverse events

Collected over Up to approximately 42 months for first course and up to approximately 57 months for second course. All-cause mortality (ACM): Up to approximately 57 months for first and second course.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib65/101 (64.4%)67/101 (66.3%)100/101 (99%)
Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo67/100 (67%)53/100 (53%)99/100 (99%)
Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo(Second Course)0/2 (0%)1/2 (50%)1/2 (50%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo(Second Course)
PneumoniaInfections and infestations12/10116/1001/2
PneumonitisRespiratory, thoracic and mediastinal disorders7/1018/1000/2
Platelet count decreasedInvestigations7/1014/1000/2
Alanine aminotransferase increasedInvestigations5/1016/1000/2
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1016/1000/2
AnaemiaBlood and lymphatic system disorders6/1013/1000/2
Aspartate aminotransferase increasedInvestigations5/1013/1000/2
Neutrophil count decreasedInvestigations1/1014/1000/2
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1014/1000/2
Blood creatinine increasedInvestigations4/1010/1000/2
Most frequent other events
Showing 10 of 80
Most frequent other events
EventPemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboPemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo(Second Course)
AnaemiaBlood and lymphatic system disorders84/10182/1000/2
Neutrophil count decreasedInvestigations83/10174/1000/2
White blood cell count decreasedInvestigations78/10170/1000/2
Aspartate aminotransferase increasedInvestigations67/10161/1000/2
Platelet count decreasedInvestigations65/10147/1000/2
Alanine aminotransferase increasedInvestigations63/10158/1000/2
PyrexiaGeneral disorders17/10117/1001/2
Amylase increasedInvestigations21/10118/1001/2
Urinary occult blood positiveInvestigations7/1016/1001/2
HypoproteinaemiaMetabolism and nutrition disorders12/1019/1001/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
Mean59.0 ± 8.660.9 ± 8.259.9 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
Female232649
Male7874152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino101100201
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
American Indian or Alaska Native000
Asian101100201
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
ECOG = 0202141
ECOG = 18179160
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
TPS = < 50%7781158
TPS = ≥ 50%241842
Not Evaluable011
Geographic Region
Geographic Region(Participants)Pemetrexed+Platinum Chemotherapy+Pembrolizumab+LenvatinibPemetrexed+Platinum Chemotherapy+Pembrolizumab+PlaceboTotal
East Asia101100201
Non-East Asia000
08

Study locations

19 sites
  • Peking Union Medical College Hospital ( Site 0108)
    Beijing, Beijing Municipality 100006, China
  • Cancer Hospital Chinese Academy of Medical Science ( Site 0117)
    Beijing, Beijing Municipality 100021, China
  • Beijing Cancer Hospital ( Site 0120)
    Beijing, Beijing Municipality 100036, China
  • The Second Hospital Affiliated to AMU ( Site 0119)
    Chongqing, Chongqing Municipality 400037, China
  • First Affiliated Hospital of The Third Military Medical University ( Site 0118)
    Chongqing, Chongqing Municipality 400038, China
  • Fujian Provincial Cancer Hospital ( Site 0102)
    Fuzhou, Fujian 350014, China
  • Southern Medical University Nanfang Hospital ( Site 0121)
    Guangzhou, Guangdong 510515, China
  • The Third Affiliated Hospital of Harbin Medical University ( Site 0100)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 0112)
    Zhengzhou, Henan 450008, China
  • Wuhan Union Hospital ( Site 0123)
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital ( Site 0122)
    Wuhan, Hubei 430079, China
  • Zhongshan Hospital Fudan University ( Site 0103)
    Shanghai, Hunan 200032, China
  • Jilin Cancer Hospital ( Site 0115)
    Changchun, Jilin 130103, China
  • Shanghai Pulmonary Hospital ( Site 0101)
    Shanghai, Shanghai Municipality 200443, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0111)
    Tianjin, Tianjin Municipality 300060, China
  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)
    Urumuqi, Xinjiang 830000, China
  • The First Affiliated Hospital Zhejiang University ( Site 0109)
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital ( Site 0113)
    Hangzhou, Zhejiang 310022, China
  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)
    Wenzhou, Zhejiang 325000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Aug 2023, 45 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Jan 20, 2021
StartActual
Nov 5, 2019
Primary completionActual
Aug 11, 2023
CompletionActual
Aug 30, 2024
Results first posted
Oct 4, 2024
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04716933
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 20, 2021
Start date
Nov 5, 2019
Primary completion
Aug 11, 2023
Completion
Aug 30, 2024
Results posted
Oct 4, 2024
Last update
Sep 9, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion